Previous 10 | Next 10 |
2024-05-28 12:02:07 ET More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic SA Asks: Who will launch the next bi...
2024-05-28 08:30:00 ET Summary Novo Nordisk stock has easily outperformed the market over the past year. Novo Nordisk's growth potential through its weight loss drugs is expanding. Competition from rivals like Eli Lilly and Amgen could impact demand and pricing dynamics in the...
2024-05-28 06:19:07 ET Summary Novo Nordisk reported great first quarter results again but free cash flow declined - in part due to high capital expenditures. At this point, we can expect the obesity market to continue growing with a high pace, but we should not ignore the increas...
2024-05-27 07:02:07 ET Summary Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss. The obesity treatment market is expected to grow exponentially, reaching $77 billion by 2030, creating a signific...
2024-05-26 22:40:47 ET Summary Novo Nordisk is a Danish pharmaceutical company specializing in treatments for diabetes, obesity, and rare diseases. The company's main source of income comes from diabetes treatments, including insulin products and GLP-1 receptor agonists. Novo ...
2024-05-26 15:19:39 ET Summary Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of tirzepatide in the near- and possibly medium-term should only be limi...
2024-05-26 13:36:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic SA Asks: Is Eli Lilly or Novo ...
2024-05-26 06:53:00 ET With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen 's (NASDAQ: AMGN) latest attempt to develop a therapy for obesity is looking like it could be a contender for the crown that's currently jointly held by...
2024-05-25 09:15:00 ET Novo Nordisk (NYSE: NVO) has been a fantastic, market-beating stock to own for the past decade. Its 10-year return is an incredible 527%, which dwarfs the S&P 500 's 182% gain during the same period. But it wasn't until 2022 that the stock really took ...
2024-05-25 08:41:46 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk once weekly insulin fails to get thu...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...